The BAT-VTE clinical trial project (Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets) has achieved a major milestone by securing international funding. It was selected as one of seven projects globally to receive funding under the EFFECT Trial call, a program supported by the ERA4Health Partnership via the European Union.
This pragmatic academic trial evaluates a therapeutic de-escalation strategy in patients with venous thromboembolic disease receiving antiplatelet therapy, aiming to reduce the risk of bleeding without compromising efficacy. While data are reassuring in patients receiving anticoagulation for atrial fibrillation, the question remains open in patients requiring anticoagulation for VTE, a distinct population.
The study has the potential to inform future clinical guidelines and standardize care for this complex and growing patient population. "The trial seeks to provide robust evidence to guide safer and more effective management of venous thromboembolism in patients receiving antiplatelet therapy", a statement indicated.
The project is coordinated by Dr. Laurent Bertoletti, Hospital Practitioner at Jean Monnet University in Saint-Étienne (France). It involves two national coordinators: Dr. Roberto Pola from Fondazione Policlinico Universitario Agostino Gemelli (Italy) and Dr. David Jiménez from the Ramón y Cajal Health Research Institute (IRYCIS), with additional support from ECRIN and SCREN (Spain).
The Spanish institution acts as the National Coordinating Centre. The team is led by Dr. David Jiménez Castro, with Dr. Raquel Morillo Guerrero as Co-Principal Investigator. They are the Head and a member, respectively, of the Respiratory Diseases group. Spain will contribute to this project with a total of 8 clinical recruitment sites from a geographically wide range.
"Congratulations to the IRYCIS team for being part of this excellent European consortium. Their participation will contribute significantly to advancing knowledge in the management of venous thromboembolism", stated a source.
The project is supported by the ERA4Health Partnership and funded in Spain by the Carlos III Health Institute (ISCIII), highlighting the importance of coordinated European efforts to advance health research and innovation.
